Transfusion of the Patient with Acquired Coagulation Defects

An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

“…Plasma is used to treat single coagulation factor or antithrombotic protein deficiencies for which no concentrates are available, as well as multiple coagulation factor and antithrombotic protein deficiencies, and for TPE 18,19 . Administration of plasma carries the risk of transfusion‐transmitted infection (TTI).…”

“…Plasma is used to treat single coagulation factor or antithrombotic protein deficiencies for which no concentrates are available, as well as multiple coagulation factor and antithrombotic protein deficiencies, and for TPE. 18,19 Administration of plasma carries the risk of transfusiontransmitted infection (TTI). Since plasma is essentially a cell-free product, the major risks of TTI are for cell-free viruses and bacteria, either from the donor or from contamination occurring during blood collection.…”

Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

“…FFP is used to treat congenital coagulation factor deficiencies, for which specific concentrates are not available, and complex coagulopathy due to acquired deficiency of multiple factors 23,24 . Posttransfusion coagulation factor activities correlate with clinical responses, 25 and patients with congenital factor deficiencies provide a unique population in which to measure the posttransfusion recovery and kinetics of individual coagulation factors.…”